A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)

Summary

To assess the efficacy and safety of FOY-305 in patients with SARS-CoV-2 infection (COVID-19) in a placebo-controlled, multicenter, double-blind, randomized, parallel-group comparative study.

Timeline

Start

2020-11-09

Primary completion

2021-03-26

Completion

2021-04-09

Publications

• Shapira S, Vishnevsky G, Yaakobi H, Shenberg G, Motlaq M, Liberman E, Kalisky A, Benari G, Tsiodras S, Adi N, Lotvall J, Arber N. Reduced Mortality in COVID-19 Patients Treated With Inhaled Extracellular Vesicles Expressing CD24. J Extracell Vesicles. 2026 Mar;15(3):e70253. doi: 10.1002/jev2.70253.
• Kinoshita T, Shinoda M, Nishizaki Y, Shiraki K, Hirai Y, Kichikawa Y, Tsushima K, Shinkai M, Komura N, Yoshida K, Kido Y, Kakeya H, Uemura N, Kadota J. A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study). BMC Med. 2022 Sep 27;20(1):342. doi: 10.1186/s12916-022-02518-7.

Drugs

Indications